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Key messages
What is already known about this subject?
 ► Autoantibodies (AAbs) are used as biomarkers 
in autoimmune diseases such as rheumatoid 
arthritis or systemic lupus erythematosus. In 
these and other plethora of disorders, they can 
be detected at asymptomatic stages.
 ► Although the presence of AAbs has been 
reported in the serum of patients with 
osteoarthritis (OA), they had not been 
previously associated with the incidence or 
progression of this disease.
What does this study add?
 ► A specific panel of AAbs has been detected 
at baseline in individuals developing incident 
radiographic knee OA (KOA) during a 96- month 
follow- up period, compared with those who 
remained healthy.
 ► Reactivity levels of AAbs against the beta 
subunit of the methionine adenosyltransferase 
(MAT2β-AAb) II enzyme are positively 
correlated with the time to OA incidence.
How might this impact on clinical practice or 
future developments?
 ► The addition of MAT2β-AAb to a prognostic 
clinical model of incident radiographic KOA 
might significantly improve the identification at 
baseline of those individuals who will develop 
the disorder during a follow- up period of 96 
months.
AbsTrACT
Objective To find autoantibodies (aabs) in serum that 
could be useful to predict incidence of radiographic knee 
osteoarthritis (Koa).
Design a nucleic- acid Programmable Protein arrays 
(naPPa) platform was used to screen aabs against 2125 
human proteins in sera at baseline from participants 
free of radiographic Koa belonging to the incidence and 
non- exposed subcohorts of the osteoarthritis initiative 
(oai) who developed or not, radiographic Koa during 
a follow- up period of 96 months. naPPa- elisa were 
performed to analyse reactivity against methionine 
adenosyltransferase two beta (MaT2β) and verify the 
results in 327 participants from the same subcohorts. The 
association of MaT2β-aab levels with Koa incidence 
was assessed by combining several robust biostatistics 
analysis (logistic regression, receiver operating 
characteristic and Kaplan- Meier curves). The proposed 
prognostic model was replicated in samples from the 
progression subcohort of the oai.
results in the screening phase, six aabs were found 
significantly different at baseline in samples from 
incident compared with non- incident participants. in 
the verification phase, high levels of MaT2β-aab were 
significantly associated with the future incidence of 
Koa and with an earlier development of the disease. 
The incorporation of this aab in a clinical model for the 
prognosis of incident radiographic Koa significantly 
improved the identification/classification of patients who 
will develop the disorder. The usefulness of the model to 
predict radiographic Koa was confirmed on a different 
oai subcohort.
Conclusions The measurement of aabs against MaT2β 
in serum might be highly useful to improve the prediction 
of oa development, and also to estimate the time to 
incidence.
InTrODuCTIOn
Osteoarthritis (OA) is the most common arthritic 
disease involving movable joints and it is increas-
ingly important in current ageing populations, 
leading to patient chronic disability.1 2 The current 
diagnostic methods are insensitive to detect the 
small changes occurring at early stages, when OA is 
characterised as an asymptomatic disease.1 To solve 
this problem, a molecular level of interrogation is 
hypothesised as the only alternative to detect the 
earliest phases of the disease process.2
Although OA is not considered an autoimmune 
disease, cell stress and extracellular matrix degra-
dation may activate maladaptive repair responses, 
including pro- inflammatory pathways of innate 
immunity.3 Activation of the immune response 
usually involves the production of immuno-
globulins against self- proteins or autoantibodies 
(AAbs), which can be detected in sera and used as 
biomarkers for early diagnosis.4 5 In this field, the 
Nucleic- Acid Programmable Protein Array (NAPPA) 
strategy has been widely used to detect AAbs in a 
high- throughput manner in many diseases,6 7 and 
has been employed in an exploratory study on sera 
from patients with OA.8 The NAPPA arrays are 
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Figure 1 Study design. A two- stage discovery approach (screening 
and verification) was designed to investigate the putative utility of AAbs 
to predict OA development. Sera from the non- exposed and incidence 
OAI subcohorts at baseline without radiographic KOA (KL=0–1) in 
at least one knee (target knee) were analysed in these two phases. 
Incident radiographic KOA was defined by KL ≥2 at 12–96 months of 
follow- up. In the screening phase, reactivity levels of AAbs against 2125 
proteins were evaluated in 10 pooled serum samples at baseline per 
Study Group (incident and non- incident) using the NAPPA platform. 
Each pool was prepared by mixing equal volumes of 10 individual sera. 
In the verification phase, the sensitivity and specificity of the baseline 
levels of MAT2β-AAb to predict KOA incidence was confirmed by 
applying the NAPPA- ELISA technique on a total of 327 individual sera at 
baseline, which included the 200 samples used at the screening. Then, 
a logistic regression model was developed combining different clinical 
variables and MAT2β-AAb levels. The clinical variables selected as 
covariates are listed in table 2. Finally, the proposed prognostic model 
was replicated in 108 individual sera at baseline from participants of 
the progression subcohort of the OAI without radiographic KOA. AABs, 
autoantibodies; KOA, knee osteoarthritis; KL, Kellgren and Lawrence; 
MAT2β, methionine adenosyltransferase two beta; NAPPA, Nucleic- acid 
Programmable Protein Array; OA, osteoarthritis; OAI, Osteoarthritis 
Initiative.
generated by printing full- length cDNAs encoding the target 
proteins with a tag on the surface of the array.9 Proteins are then 
transcribed and translated by a mammalian cell- free system and 
captured in situ by immobilised antibodies specific for the tag 
encoded at the carboxy- terminus of the amino acid sequence.10
The Osteoarthritis Initiative (OAI) is an ideal target popula-
tion to detect relevant biomarker characteristics of earlier stages 
of the disease. It is a multi- centre, longitudinal and observational 
cohort study that has enrolled 4796 individuals which have been 
followed during 96 months.11 12 Among all these subjects, the 
OAI comprises participants without clinically significant knee 
osteoarthritis (KOA) at baseline, but selected on the basis of 
having specific characteristics that give them an increased risk 
of developing incident symptomatic KOA (incidence subcohort), 
and a reference control group whose participants did not have 
neither symptomatic KOA nor risk factors at baseline (non- 
exposed subcohort).
In the present study, serum samples at baseline from the inci-
dence and non- exposed subcohorts of the OAI were analysed 
using NAPPA technology for the discovery of an AAb profile 
that could be associated with an early and asymptomatic stage of 
the disease. The objective was to detect AAbs useful to identify 
those asymptomatic individuals who will develop radiographic 
KOA before 96 months, and examine the putative relationship 
between their levels in serum and the time for OA incidence.
MATerIAls AnD MeTHODs
Definition of incident radiographic KOA
In this case–control study, two main outcomes group, with one 
study knee per subject (target knee), were defined: the incident 
(n=146) and the non- incident group (n=181), both without 
clinically relevant radiographic KOA at baseline (Kellgren and 
Lawrence (KL) grade=0–1) in at least one knee (target knee). 
Incident radiographic KOA was defined by KL grade ≥2 in 
the target knee at some point between 12 and 96 months of 
follow- up.
study design
A two- stage discovery approach (screening and verification) was 
designed to analyse the presence and putative usefulness of KOA- 
associated AAbs to predict the incidence of the disorder. The 
sera were blindly analysed and belonged to Caucasian partic-
ipants from the incidence and non- exposed subcohorts of the 
OAI at the baseline visit (181 non- incidents and 146 incidents at 
96 months). The prognostic clinical model generated to predict 
KOA development was later replicated in a total of 108 partici-
pants (65 non- incidents and 43 incidents at 96 months) from the 
progression subcohort of the OAI at the baseline visit. Detailed 
information about the workflow of the study is summarised and 
illustrated in figure 1.
nAPPA profiling of serum AAbs
The NAPPA core Centre for Personalised Diagnostics (CPD) 
at the Biodesign Institute (Arizona State University, USA) had 
all human genes from the DNASU ( www. dnasu. org) on six 
different array sets: HC1−HC6. The HC5 set was selected for 
the screening on the basis of having the greatest number of genes 
that could be related with OA pathogenesis according to bibli-
ography (listed in online supplementary table S1). The quality of 
DNA printing, protein expression and detection of the NAPPA 
slides were performed using the standard procedure of CPD,13 
but incubating the expressed slides overnight with 150 µL of 
1:20 (v/v) diluted serum. A titration assay was performed using 
serum dilutions from 1:20 down to 1:200 to identify an optimal 
dilution factor that provided an acceptable background without 
overwhelming the true signals.
The signal intensities obtained in the assay were normalised 
as described.14 To determine positive AAb response, a cut- off 
level was calculated by median intensity absolute deviation rule 
from all the spots through all the serum pools. The mean and 
SD of the mean were obtained for the incident and non- incident 
groups. The antigens that did not exhibit intensities over the cut- 
off were eliminated. A differential spot analysis was performed 
with the remaining antigens by Wilcoxon Rank- Sum test (p 
value<0.05) and the area under the curve (AUC) at 95% speci-
ficity were calculated using the pROC package in R. In addition, 
AAb candidates were qualitatively examined by visual analysis 
through all the slides by adjusting in identical black and full 
colour threshold scale.
nAPPA-elIsA assay
In all, 500 ng of full- length methionine adenosyltransferase two 
beta (MAT2β) human recombinant protein fused to glutathione 
S- transferase (GST) were synthesised in vitro using the HeLa cell 
lysate- based protein in vitro transcription/translation (IVTT) 
system (Thermo Fisher Scientific). NAPPA- ELISA assay was 
performed as previously described8 with some variations. 96- well 
plates coated with 40 ng of anti- GST antibody were blocked 
4 hours at room temperature with 5% milk-1×phosphate- 
buffered saline with tween (PBST) (0.02% Tween20). 50 µL 
of the IVTT- expressed recombinant human protein was trans-
ferred to each well and incubated at 4°C overnight on shaker. 
Plates were then washed and incubated with 1:20 (v/v) diluted 
sera. The presence of specific MAT2β-AAb was detected by 
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Table 1 MAT2β-AAb model assessment in the verification phase
estimate 95% CI
OR (p value) 5.99 (1.000E-03) 2.16 16.63
AUC 0.62 0.56 0.68
Sensitivity (%) 86 80 91
Specificity (%) 39 31 46
PPV (%) 53 50 57
NPV (%) 78 70 85
AUC, area under the curve;MAT2β-AAb, methionine adenosyltransferase two beta- 
autoantibody; NPV, negative predictive value; PPV, positive predictive value.
incubation with horseradish peroxidase (HRP)- linked anti- 
Human IgG (Jackson ImmunoResearch Laboratories) diluted 
1:1000 (v/v) in blocking buffer. After addition of tetramethyl- 
benzidine substrate, the absorbance signals at 450 nm were read 
on a Biotek Synergy four plate reader (Winooski, VT, USA). 
Levels of MAT2β-AAb were expressed in arbitrary units (a.u.) 
of absorbance.
Data analysis
The biological context network of MAT2β was analysed with 
the STRING (https:// string- db. org/) bioinformatics webtool, 
using the K- means clustering method. Differences in the base-
line reactivity levels of MAT2β-AAb were assessed by the Mann- 
Whitney U test and the association of this potential biomarker 
with OA incidence was evaluated with the OR. In addition, after 
assessment of cut- off values (tertiles) for MAT2β-AAb, patients 
with OA were categorised into high- level, medium- level and 
low- levels groups. Kaplan- Meier (KM) analyses were used to 
estimate and represent the survival probability, explained as the 
probability of not developing KOA in specific periods of time 
(12, 24, 36, 48, 72 and 96 months) depending on the tertiles of 
MAT2β-AAb reactivity levels of the participants.
To define prognostic models of OA, clinical data at baseline 
were obtained from the OAI database (https:// data- archive. nimh. 
nih. gov/ oai). Candidate non- radiographic clinical variables that 
may have prognostic value were selected based on the specific 
eligibility risk factor criteria for the incident subcohort of the 
OAI and prior published evidence suggesting a risk factor role 
in KOA incidence (online supplementary table S2). For all vari-
ables concerning the joint, knee- value predictors were recoded 
to indicate they were for the target knee. When neither or both 
knees have incident KOA, one of them was randomly selected 
and used in the analysis. In a primary step, univariable logistic 
regression analyses were employed to assess association between 
each variable with incident radiographic KOA. In a secondary 
step, a stepwise multivariable logistic regression analysis was 
performed to define a prognostic model of incident radiographic 
KOA.
The capacity of the models to predict OA incidence was eval-
uated using the AUC. The utility of the measurement of the 
reactivity levels of the potential biomarker was assessed by 
comparing the AUC of the covariates- only model with the AUC 
of the biomarker plus covariates model. Sensitivity, specificity 
and positive predictive value and negative predictive value were 
also estimated by the Youden Index to determine the validity 
and security of the models, and receiver operating character-
istic (ROC) curves were evaluated. A nomogram was developed 
to facilitate application of the proposed prognostic model in a 
clinical setting. Finally, the validity of the proposed biomarker 
plus covariates model was evaluated by a replication analysis 
in a different set of participants from the OAI progression 
subcohort.
All regression analyses and KM curves were carried out using 
SPSS V.25 for Mac. Metrics were calculated using the pROC 
package in R.
Patient and public involvement
This research was done without patient involvement. Patients 
were not invited to comment on the study design and were not 
consulted to develop patient relevant outcomes or interpret the 
results. Patients were not invited to contribute to the writing or 
editing of this document for readability or accuracy.
resulTs
Identification of AAbs associated with the incidence of KOA
To search for AAbs in the serum that could be associated with 
a future development of KOA, a comprehensive AAb profiling 
against 2125 full- length proteins was performed by NAPPA. It 
was carried out comparing pools of serum samples at baseline 
from two groups: the incident group, which contains partic-
ipants belonging to the incidence subcohort of the OAI who 
did develop radiographic KOA during the 96- month follow- up 
(n=100, 10 pools), and the non- incident group, which contains 
participants from the non- exposed subcohort that remained 
radiographically healthy (n=100, 10 pools).
A signal cut- off >1.1 was employed to assure a sufficient 
margin between positive and negative AAbs reactivities. Among 
the 2125 screened proteins, a total of 1031 proteins showed posi-
tive immunoreactivity (online supplementary table S3). Mean 
and SD values for all the proteins expressed on the array for 
the incident and non- incident groups are summarised in online 
supplementary table S3. From all the proteins over the cut- off, 
the Wilcoxon Rank- Sum test identified a total of six AAbs that 
reacted with six different proteins on the array (online supple-
mentary table S4). Furthermore, as shown in online supplemen-
tary figure S1, visually discernible differences demonstrated that 
the normalisation criteria employed did neither create signal 
differences that do not exist, nor destroy true signal differences.
Verification of MAT2β-AAb levels as potential prognosis 
marker of OA incidence
To confirm the putative ability of any of these AAbs to predict 
the incidence of OA, anti- MAT2β was selected to be technically 
verified by NAPPA- ELISA in 327 individual serum samples, 200 
of which (100 incidents and 100 non- incidents) were previously 
used at the screening phase. This selection was based on the 
role of MAT2β as negative regulatory subunit of the produc-
tion of S- adenosylmethionine (SAMe), a main methyl donor 
in the human body and a widely used dietary supplement for 
OA management (AdoMet). In addition, its biological context 
network (online supplementary figure S2) suggests a bottleneck 
role of this protein in metabolic pathways that are known to 
be related with OA pathogenesis. After the subtraction of the 
negative control, we found positive reactivity against MAT2β 
in all the analysed sera. The higher baseline reactivity levels 
of MAT2β-AAb found in the incident group (0.58±0.22 vs 
0.49±0.23 a.u., p=3.140E-04) verified our previous findings. 
The association of this potential biomarker with the clinical 
outcome and its ability to predict incidence of radiographic KOA 
were assessed and are summarised in table 1.
Furthermore, we detected a significant decrease in anti- MAT2β 
reactivity levels with the time to KOA onset (p value=0.002), as 
it is shown in online supplementary figure S3. The association 
between the baseline reactivity levels of MAT2β-AAb in sera and 
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Table 2 Characteristics at baseline of the study participants in the verification and replication phases
Covariates
Verification phase replication phase
Incident OA (n=146) non- incident OA (n=181) Incident OA (n=65) non- incident OA (n=43)
Age, mean years (SD) 60.65 (8.51) 56.61 (8.57) 58.26 (9.40) 59.86 (8.50)
Sex, n (%) female 98 (67.1) 102 (56.4) 26 (60.5) 25 (38.5)
BMI, mean kg/m2 (SD) 28.93 (4.59) 25.88 (4.14) 29.75 (4.94) 28.29 (3.69)
Frequent knee bending activity, n (%) yes 110 (75.3) 106 (58.6) 30 (71.4) 27 (41.5)
History of knee injury, n (%) yes 39 (26.7) 23 (12.7) 9 (21.4) 7 (10.9)
WOMAC pain score 1.63 (2.36) 0.61 (1.63) 3.21 (3.58) 1.68 (2.43)
BMI, body mass index; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 2 Association of biomarker levels with the time to KOA 
incidence. Kaplan- Meier reliability analysis for MAT2β-AAb in the OAI 
participants included in this work, classified into three groups (low 
level, medium level and high level) after the calculation of a cut- off 
value (MAT2β-AAb tertiles). *Level of significance below 0.05 by the 
Log- Rank test. KOA, knee osteoarthritis; MAT2β-AAb, methionine 
adenosyltransferase two beta- autontibody; OAI, Osteoarthritis Initiative.
the time to OA incidence were inferred by KM curves (figure 2). 
Individuals with low AAb levels at baseline (range=2.00E-3–0.39 
a.u.) had a significant lower risk to develop KOA sooner in time 
than those with high (range=0.60–1.58 a.u., p=2.440E-04) or 
medium (range=0.39–0.60 a.u., p=5.000E-06) baseline levels. 
There were no significant differences in the time to KOA inci-
dence when the high- level and medium- levels groups were 
compared (p=0.267).
Predictive modelling of KOA incidence with the combination 
of clinical variables and MAT2β-AAb levels
A unique covariates- only model including age, sex, body mass 
index (BMI), frequent knee bending activity, history of knee 
injury and the Western Ontario and McMaster Universities 
Osteoarthritis Index pain score was defined by stepwise multi-
variable logistic regression analysis. The clinical characteristics 
finally included in the model of the selected participants are 
presented in table 2. The results from the univariable logistic 
regression model of all the clinical variables analysed are shown 
in online supplementary table S5.
The clinical model defined herein yielded an AUC (95% CI) 
of 0.81 (0.76–0.86). The addition of MAT2β-AAb to this model 
significantly improved the capacity to predict radiographic KOA 
development in the target knee (p=0.048), yielding an AUC of 
0.83 (0.78–0.87). Figure 3A,B shows the results from this regres-
sion analysis, together with the metrics and the ROC curves 
obtained when comparing the covariates- only model with the 
MAT2β-AAb plus covariates model.
To facilitate the use of the proposed prognostic model in a 
clinical routine, a nomogram was developed (figure 3C) to 
determine the probability of a certain individual to develop KOA 
in the next 96 months.
replication analysis in an independent OAI subcohort
The proposed MAT2β-AAb plus covariates model was repli-
cated in an independent set of sera at baseline from participants 
without KOA belonging to the progression subcohort of the OAI. 
The clinical characteristics of this population are summarised in 
table 2. The AUC observed in this replication analysis was 0.76 
(table 3), showing no significant differences with that obtained 
in the verification phase (p=0.218). In addition, the sensitivity, 
specificity and predictive values remained very similar in both 
verification and replication cohorts.
DIsCussIOn
One of the features of a prognostic marker is the ability to predict 
the future occurrence of a certain disease among people who do 
not have it.15 The production of antibodies against self- proteins 
is a characteristic feature of many diseases.16 Considering the 
fact that AAbs can often be detected at asymptomatic stages,4 
they might have the potential to identify susceptible individuals 
or populations and facilitate prognosis. The idea that AAbs can 
be used to predict a disease state has been extensively studied in 
different disorders, such as cancer17–19 or type 1 diabetes.20 21 In 
the field of rheumatic diseases, AAbs have a fundamental value 
in the diagnosis of those with an autoimmune pathogenesis, such 
as systemic lupus erythematosus22 and rheumatoid arthritis.23
Although OA is not considered an autoimmune disorder, the 
immune system is highly related with early disease.24 However, 
existing literature related to the presence of AAbs in patients 
with OA is limited.8 25–27 Indeed, this is the first study that eval-
uates the usefulness of AAbs to stratify patients with asymptom-
atic OA. The use of a large- scale approach (NAPPA) enabled the 
search of a massive number of putative AAbs, which is the largest 
screening performed to date in the OA field. With this approach, 
we have identified significant levels of reactivity from AAbs 
against six different proteins that are associated with the future 
incidence of the disease. At this point, a characteristic of this 
approach should be taken into consideration when interpreting 
the findings presented herein: The low sera dilutions employed 
in this work lead to the primary detection of class M immuno-
globulins (IgM), which, in contrast to IgGs, have no immune 
memory. However, IgMs are not subjected to immunoregula-
tion28 and are formed early in the immune response. Therefore, 
specific antibodies of the IgM class might be important in the 
diagnosis of chronic diseases.29
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Figure 3 Prognostic model for incident radiographic KOA. (A) Metrics comparing the covariates- only model with the biomarker plus covariates 
model. (B) ROC curve for the models. (C) Nomogram of the biomarker plus covariates prognostic model. To use the nomogram, a straight edge on 
the top of the figure identifies the value on the points scale that corresponds to the score for each predictor (black arrows pointing up). In addition, 
the straight edge is aligned with the total points to determine probability at the bottom of the nomogram, once all the points for each predictor are 
summed. For example, a woman (18 points) of 45- year old (0 points), with a BMI of 23 kg/m2 (27 points), who is involved in an activity with frequent 
knee bending (21 points), with no history of injury (0 points), a WOMAC pain score of 2.5 (10 points), and whose reactivity levels of MAT2β-AAb 
in serum were 1.2 a.u. (57.5 points) renders a total of 133.5 points. This value gives her a probability of 55.5% to develop radiographic KOA within 
a period of 96 months (red arrow pointing down). a.u., arbitrary units; AUC, area under the curve; BMI, body mass index; KOA, knee osteoarthritis; 
MAT2β-AAb, methionine adenosyltransferase two beta- autontibody; NPV, negative predictive value; OA, osteoarthritis; PPV, positive predictive value; 
ROC, receiver operating characteristic; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Table 3 Predictive capacity of the MAT2β-AAb plus covariates 
model in the verification and replication phases




AUC (95% CI) 0.83 (0.78 to 0.87) 0.76 (0.66 to 0.86) 0.218
Sensitivity % (95% CI) 80 (73 to 86) 71 (56 to 83)
Specificity % (95% CI) 75 (68 to 81) 81 (70 to 91)
PPV % (95% CI) 72 (66 to 77) 71 (60 to 83)
NPV % (95% CI) 83 (77 to 87) 81 (74 to 89)
AUC, area under the curve;MAT2β-AAb, methionine adenosyltransferase two beta- 
autontibody; NPV, negative predictive value; PPV, positive predictive value.
The results for MAT2β-AAb have been verified on 327 indi-
vidual samples at baseline from the OAI cohort, which provides 
a robust evaluation of its ability to classify patients at baseline 
as incident or non- incident during a 96- month period. More-
over, KM curves showed a significant association of the baseline 
reactivity levels of MAT2β-AAb with the time of KOA appear-
ance. This statistical approach has been widely used in cancer 
biomarkers30–32 and it has been recently introduced in the rheu-
matology field.33 34 Interestingly, our results showed that higher 
baseline reactivity levels of this AAb result in a sooner develop-
ment of radiographic KOA.
MAT2β is the regulatory subunit responsible of enhancing or 
inhibiting the synthesis of SAMe. This latter compound plays 
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a vital role in methylation, transsulfuration and aminopropyla-
tion pathways,35 and it has been employed as dietary supple-
ment for OA management.35–38 Although there is no evidence of 
the direct involvement of MAT2β in OA, its fundamental role 
in key biological processes for the pathogenesis of this disease 
(online supplementary figure S2) turns it into a potential marker 
of interest. Curiously, this protein was not included in either the 
planar arrays or the NAPPA developed previously by our group 
for the screening of OA- associated AAb.8
The MAT2β-AAb- only model showed a modest ability to 
predict radiographic KOA development, yielding an AUC 
of 0.62 with 39% specificity and 86% sensitivity. In the OA 
field, this modest predictive capacity is in agreement with that 
obtained for different biomarkers that have been evaluated in 
the last years to predict relevant OA progression. For example, 
Eckstein and collaborators examined the relationship of 15 
molecular markers with structural progression based on femo-
rotibial cartilage loss.39 The strongest predictors of longitudinal 
thinning were serum C- terminal telopeptide of collagen type I 
(CTX- I) and plasma N- terminal propeptide of type II procol-
lagen, yielding AUCs of 0.65 and 0.64, respectively, but all the 
remaining biomarkers showed AUCs<0.60. Furthermore, in 
the meta- analysis published by Valdes and collaborators,40 urine 
CTX- II also showed a limited predictive capacity (AUC ≤0.63). 
Recently, Kraus and collaborators have investigated a target 
set of 18 biochemical markers (baseline and time- integrated 
concentrations (TICs) over 12 and 24 months) as predictors of 
symptomatic and radiographic KOA progression.41 Among all 
of them, the best single biomarker was the 24 M TIC CTX- II 
measured in urine, yielding an AUC=0.58.
With the aim of defining a useful non- radiographic prognostic 
model focused on KOA, different non- radiographic clinical 
factors related with risk of incident KOA in the literature42–44 
have been analysed in this study by univariable logistic regres-
sion analysis to look for significant predictors. It is important to 
specify that this study is based on a Caucasian US population, 
which may not comprise all the factors that enhance predisposi-
tion to OA. Among the clinical variables finally included in the 
model, the history of knee injury showed the highest OR, which 
was markedly lower than the reactivity levels of MAT2β–AAb 
(OR 2.57 vs 5.99) for being incident. As shown herein, the use 
of stepwise multivariable regression analysis resulted in one 
prognostic model of KOA incidence with an AUC=0.81. Using 
data from individuals in the Rotterdam study, a prediction model 
using clinical factors that yields an AUC of 0.66 was defined.45 
In another study, Zhang and collaborators defined a model of 
incidence of radiographic KOA with data from the Nottingham 
cohort, the OAI cohort and the Genetics of Osteoarthritis and 
Lifestyle (GOAL) study.46 This model, including variables such 
as age, gender, BMI, occupational risk, family history and knee 
injury yielded the greatest AUC (0.74) in the GOAL popula-
tion, compared with the OAI (AUC=0.60) and the Nottingham 
(AUC=0.69). In our case, the remarkably high ability to predict 
the appearance of radiographic KOA using this covariates- only 
model could be due to the high prevalence of the disease in our 
verification cohort (45% of incident participants). Indeed, the 
application of this model into the whole OAI database yielded a 
lower AUC (AUC <0.70 (data not shown)).
Despite the rather low AUC of MAT2β-AAb, the addition of 
this potential biomarker to the prognostic covariates- only model 
led to an increase in its discriminative ability (AUC=0.83), 
being this increase statistically significant (p=0.048). A similar 
improvement, but in this case not significant, was previously 
reported by including uCTX- II levels in a clinical prediction 
model for KOA.45 At this point, it is important to take into 
account that among all the patients involved in this study, 42.5% 
of them had already developed radiographic OA in the off- target 
knee (KL ≥2). Nevertheless, we observed that the prognostic 
ability of MAT2β-AAb levels is maintained after removing 
subjects with contralateral OA at baseline (AUC=0.61 (0.54–
0.68)). In addition, the inclusion of the presence of contralateral 
OA to the proposed MAT2β-AAb plus covariates model did not 
improve its predictive capacity (p=0.093). This strengthens the 
utility of this biomarker to predict incidence of KOA without 
the need of any radiographical information from the patients, 
avoiding their exposure to harmful radiation. Finally, the prog-
nostic model combining baseline levels of MAT2β-AAb with 
clinical variables was replicated in an independent population, 
which confirms its putative utility to predict the appearance of 
radiographic KOA and strongly suggests it can be generalisable 
to the wider population.
In summary, the present study shows that a high antibody reac-
tivity against MAT2β protein in serum is associated at baseline 
with individuals who will develop incident radiographic KOA, 
and also with an earlier appearance of the disease. Our results 
suggest that the inclusion of MAT2β-AAb in a clinical prognostic 
model for radiographic KOA could improve the identification of 
individuals who will develop the disease before 96 months.
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